Pfizer’s valuation story turns to pipeline progress, oncology pressure, earnings strength, and healthcare execution after a ...

Pfizer is drawing renewed market attention as healthcare strength, pharmaceutical deal activity, and defensive demand reshape ...

Pfizer's stock has fallen more than 50% from its 2021 high. The stock is trading below its pre-coronavirus pandemic level. Pfizer is dealing with what are, in reality, just normal headwinds in the ...

Pfizer (PFE) is back in focus for investors as its latest reported figures offer a snapshot of how the US$143.7b pharmaceutical group is positioned, with value metrics and recent returns drawing ...

Explore the exciting world of Pfizer (NYSE: PFE) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential ...

Pfizer (NYSE: PFE) is a high-yielding stock that's trading at a low valuation. The problem is, it's been that way for some time now. The stock's lack of movement in one direction or another seems to ...

It could prove to be a case of better later than never for the healthcare giant.

Pfizer (NYSE: PFE) was founded in 1849. That makes the company well over 100 years old. Not many companies have managed to survive as long as Pfizer has, especially in an industry as highly technical ...

Shares of the pharmaceutical giant trade at less than 9 times its future earnings. Investors are likely concerned about upcoming patent cliffs that may weigh down its financials. However, the company ...